Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment
Effect of NR3C2 genetic polymorphisms on the blood pressure response to enalapril treatment
复制标题
NR3C2 基因多态性对依那普利治疗血压反应的影响。
DOI：
10.2217/pgs.13.173
复制
发表时间：
2014-02-01
期刊：
影响因子：
2.1
通讯作者：
Zhang, Wei
中科院分区：
文献类型：
--
作者：
Luo, Jian-Quan;Wang, Lu-Yan;Zhang, Wei
目的：矿化皮质激素受体（MR，又称NR3C2）在血压调节中起重要作用。研究NR3C2多态性对依那普利降压疗效的影响。患者与方法：采用Sequenom MassArray技术对279例接受依那普利治疗的原发性高血压患者进行NR3C2标记snp rs5522和rs2070950基因分型。结果：rs5522多态性AA纯合子舒张压（DBP）的降低明显高于AG+GG基因型携带者（p = 0.009）， rs2070950多态性GG纯合子舒张压（DBP）的降低明显高于GC+CC基因型携带者（p = 0.065）。逐步多元回归分析显示基线DBP （p < 0.001）、腰臀比（p = 0.001）和rs5522基因型（p = 0.003）是DBP降低的显著预测因子。结论：NR3C2 rs5522可影响依那普利治疗后的血压反应，可作为原发性高血压患者对依那普利降压反应的药物基因组学标志物。最初提交于2013年8月8日；修订提交2013年8月29日；2013年9月23日在线发布
Aim: The mineralocorticoid receptor (MR; also known as NR3C2) plays important roles in the modulation of blood pressure. The effect of NR3C2 polymorphisms on antihypertensive response to enalapril was investigated. Patients & methods: Two hundred and seventy nine essential hypertension patients treated with enalapril were genotyped for two NR3C2 tagSNPs, rs5522 and rs2070950, by Sequenom MassArray technology. Results: The reductions in diastolic blood pressure (DBP) were significantly greater in AA homozygotes compared with AG+GG genotype carriers for the rs5522 polymorphism (p = 0.009), and the reductions in DBP were greater in GG homozygotes compared with GC+CC genotype carriers for the rs2070950 polymorphism, with marginal significance (p = 0.065). Stepwise multiple regression analysis indicated that significant predictors of DBP reduction were baseline DBP (p < 0.001), waist:hip ratio (p = 0.001) and rs5522 genotype (p = 0.003). Conclusion:NR3C2 rs5522 affects blood pressure response to enalapril treatment and may serve as a useful pharmacogenomic marker of antihypertensive response to enalapril in essential hypertension patients. Original submitted 8 August 2013; Revision submitted 29 August 2013; Published online 23 September 2013